Biopharma CEO Fireside Chat

 

Moderator:

Brooke Paige, CSAP
Digital Health Alliance Leader
Former VP, Pear Therapeutics

Having worked in the biopharmaceutical industry for over 20 years, Brooke has worked with numerous commercial, development, research and academic alliances, and has been a frequent speaker on trends in the alliance space.

As a Sloan Fellow at London Business School, Brooke wrote her graduate thesis on how to optimally structure and manage biopharma alliance collaborations, and subsequently became one of the first Alliance Managers in the biopharma industry. She is a Certified Strategic Alliance Professional (CSAP), and was elected to the Board of ASAP, the Association of Strategic Alliance Professionals in 2014, serving as Chairman of the Board since 2016.

Prior to joining Pear, Brooke was Staff Vice President of Marketing, Communications & Alliance Management (MCAM), and Chief of Staff at HealthCore, Inc., the research arm of Anthem, Inc. In this capacity, she was responsible for alliance management, marketing, internal and external communications, strategic planning, and innovation management during a time of exponential growth. Earlier in her career, she was a launch marketer, having contributed to two brands which were ultimately ranked in the top 10 global products by lifetime sales.

Brooke possesses extensive global experience, having lived and worked in several countries, including the UK, Germany, France and Japan. She is a high honors graduate of Mount Holyoke College, and was a Sloan Fellow at London Business School. In 2011, Brooke became the 88th woman in the world to run a marathon on all seven continents.

Panelists:

Andrew S. Eibling, CSAP
President & CEO
GeniPhys

Andy Eibling is an experienced senior leader with over thirty years of experience in the life sciences industry specializing in soliciting, analyzing, negotiating, and managing strategic partnerships.

During his time working for a top 20 pharma company, a leading contract research organization, and various startups, he has been involved in a wide range of partnerships, from major global joint ventures and multi-billion-dollar strategic provider relationships to early-stage technology deals. His experience has allowed him to gain multiple perspectives firsthand - as a pharma company, service provider, and life science startup.

Andy joined GeniPhys as CEO in April of 2021. GeniPhys is a preclinical-stage regenerative medicine company founded out of Purdue University and is developing a revolutionary collagen polymer that enables tissue regeneration without invoking inflammation.

Prior experiences include founding Forty86, a consulting form specializing in business development and partnering strategy. Andy also served as VP of Business Development and Alliance Management at Enable Injections, a MedTech startup, where he was responsible for all commercial activities, including establishing and maintaining strategic alliances with biopharma partners.

Andy's career also includes eight years at Covance as VP of Enterprise Alliance Management, and 24 years at Eli Lilly & Company, where, as a founding member of Lilly's pioneering Office of Alliance Management, he managed a variety of partnerships ranging from early discovery technologies to global drug development.

Dr. Krishnan Viswanadhan
President & Chief Operating Officer
Be Biopharma

Dr. Krishnan Viswanadhan is a biopharmaceutical executive with over 20 years of broad cross-functional experience in advancing new medicines for patients with serious and life-threatening diseases. Krishnan is current President and Chief Operating Officer at Be Biopharma, a leader in engineered B cells as a new category of medicines for patients with serious diseases.

Prior to Be Bio, Krishnan was Senior Vice President, Global Cell Therapy Franchise Lead at Bristol Myers Squibb where he was responsible for overseeing the integrated cell therapy franchise strategy across the enterprise including building core capabilities and key investments to support long term growth. He oversaw the teams responsible for the development, approval, and life cycle management of Breyanzi, a CD19 CAR T and Abecma, the first BCMA CAR T therapy.

Prior to BMS, Krishnan was Vice President, Business Development and Global Alliances at Celgene Corporation responsible for managing the portfolio of partnerships and equity investments. Prior to Celgene, Krishnan had roles in large and small companies in regulatory strategy.

Dr. Viswanadhan is a registered Pharmacist and received his Doctor of Pharmacy degree from Rutgers University and holds a Master of Business Administration degree from Cornell University.

Krishnan currently serves the board as a non-executive director of JW Therapeutics, a leading cell therapy company in China.